Abstract

Abstract Background: Despite the efficacy of vitamin K antagonists against stroke in patients with atrial fibrillation (AF), the underuse of this therapy is well documented. Objectives: To evaluate trends and predictors of oral anticoagulants utilization in patients with AF. Methods: Observational, retrospective, serial cross-sectional study between 2011-2016. Comparisons between groups were performed using the Student t, Mann-Whitney and Chi-square tests. Logistic regression was used to identify independent predictors of anticoagulation. A p value < 0.05 was considered significant. Results: A total of 377 patients were analyzed. The mean age was 70 ± 15 years; 52% were male and 75% were anticoagulated (20% with VKA and 55% with DOAC). Over 5 years, the overall frequency of anticoagulation increased by 22.4%. The use of DOACs increased from 29% to 70%, whereas the use of VKA decreased from 36% to 17%. The use of antiplatelet agents alone also fell from 21% to 6%. The predictors of anticoagulation were previous episodes of AF (OR 3.1, p < 0.001), hypertension (OR 3.0, p < 0.001) and HASBLED score (OR 0.5, p < 0.001). The predictors of DOAC use were serum creatinine (OR 0.2, p = 0.002), left atrial size (OR 0.9, p = 0.003) and biological valve prosthesis (OR 0.1, p = 0.007). Of the 208 patients using DOACs, 63 (30%) received inadequate prescriptions: 5 with severe drug interactions and 58 with incorrect dosing. Conclusions: Between 2011 and 2016, DOACs were rapidly incorporated into clinical practice, replacing AVKs and antiplatelets, and contributing to greater use of anticoagulation in patients with AF.

Highlights

  • Atrial fibrillation (AF) affects about 1–2% of the world’s population and is associated with a five-fold increased risk of stroke

  • The group on anticoagulants was subsequently divided into patients using vitamin K antagonists (VKA) or direct-acting oral anticoagulants (DOACs) (Table 1)

  • The mean age of the patients was 70 ± 15 years, and 52% were male with mean body mass index (BMI) of 27 ± 6

Read more

Summary

Introduction

Atrial fibrillation (AF) affects about 1–2% of the world’s population and is associated with a five-fold increased risk of stroke. The use of vitamin K antagonists (VKA) as anticoagulants reduces the risk of stroke or systemic embolism by 64% and all-cause death by 26%.1-7. Over the past 10 years, several randomized trials, involving more than 70,000 patients with AF, compared the use of AVK with direct-acting oral anticoagulants (DOACs). In these studies, DOACs were at least as effective as VKAs in preventing thromboembolic events and promoted a significant reduction in the frequency of intracranial hemorrhage.[11] In addition, DOACs. Despite the efficacy of vitamin K antagonists against stroke in patients with atrial fibrillation (AF), the underuse of this therapy is well documented. Conclusions: Between 2011 and 2016, DOACs were rapidly incorporated into clinical practice, replacing AVKs and antiplatelets, and contributing to greater use of anticoagulation in patients with AF. (Int J Cardiovasc Sci. 2020;33(1):68-78) Keywords: Atrial Fibrillation; Anticoagulants; Brain Ischemia; Vitamin K/antagonists & inhibitors; Thromboembolism/ prevention & control

Objectives
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.